U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Trump Administration Signals Tougher Stance on Citizenship Revocation for Fraud Convictions 
Trump Administration Pauses Immigrant Visa Processing for Applicants From 75 Countries 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
U.S. Schools Set to Bring Back Whole Milk After 15-Year Ban 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Pentagon Prepares Alaska Troops for Possible Minnesota Deployment Amid Immigration Protests 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Minnesota U.S. Citizen Detained by ICE in Armed Raid Sparks Outrage and Civil Rights Concerns 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
